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Abstract
Background: Healthcare-associated infections caused by Pseudomonas aeruginosa are associated with poor
outcomes. However, the role of P. aeruginosa in surgical site infections after colorectal surgery has not been
evaluated. The aim of this study was to determine the predictive factors and outcomes of surgical site infections
caused by P. aeruginosa after colorectal surgery, with special emphasis on the role of preoperative oral antibiotic
prophylaxis.
Methods: We conducted an observational, multicenter, prospective cohort study of all patients undergoing
elective colorectal surgery at 10 Spanish hospitals (2011–2014). A logistic regression model was used to identify
predictive factors for P. aeruginosa surgical site infections.
Results: Out of 3701 patients, 669 (18.1%) developed surgical site infections, and 62 (9.3%) of these were due to P.
aeruginosa. The following factors were found to differentiate between P. aeruginosa surgical site infections and those
caused by other microorganisms: American Society of Anesthesiologists’ score III–IV (67.7% vs 45.5%, p = 0.001, odds
ratio (OR) 2.5, 95% confidence interval (95% CI) 1.44–4.39), National Nosocomial Infections Surveillance risk index 1–2
(74.2% vs 44.2%, p < 0.001, OR 3.6, 95% CI 2.01–6.56), duration of surgery ≥75thpercentile (61.3% vs 41.4%, p = 0.003, OR
2.2, 95% CI 1.31–3.83) and oral antibiotic prophylaxis (17.7% vs 33.6%, p = 0.01, OR 0.4, 95% CI 0.21–0.83). Patients with
P. aeruginosa surgical site infections were administered antibiotic treatment for a longer duration (median 17 days
[interquartile range (IQR) 10–24] vs 13d [IQR 8–20], p = 0.015, OR 1.1, 95% CI 1.00–1.12), had a higher treatment failure
rate (30.6% vs 20.8%, p = 0.07, OR 1.7, 95% CI 0.96–2.99), and longer hospitalization (median 22 days [IQR 15–42] vs 19d
[IQR 12–28], p = 0.02, OR 1.1, 95% CI 1.00–1.17) than those with surgical site infections due to other microorganisms.
Independent predictive factors associated with P. aeruginosa surgical site infections were the National Nosocomial
Infections Surveillance risk index 1–2 (OR 2.3, 95% CI 1.03–5.40) and the use of oral antibiotic prophylaxis (OR 0.4, 95%
CI 0.23–0.90).
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Conclusions: We observed that surgical site infections due to P. aeruginosa are associated with a higher National
Nosocomial Infections Surveillance risk index, poor outcomes, and lack of preoperative oral antibiotic prophylaxis.
These findings can aid in establishing specific preventive measures and appropriate empirical antibiotic treatment.
Keywords: Healthcare-associated infection, Surgical site infection, Colorectal surgery, Colorectal cancer, Spain
Background
Currently, surgical site infections (SSIs) are the most
frequent healthcare-associated infections (HAI) in acute-
care hospitals in Europe and the US, accounting for 20%
of all HAIs [1]. The development of an SSI lengthens pa-
tients’ hospital stay and increases readmission and mor-
tality rates 2–11 times [2]. In particular, colorectal
surgery is associated with high rates of SSI due to in-
creased possibility of contamination during the procedure,
although findings of SSI rates from studies considerably
vary due to differences in the surveillance criteria used
and the quality of data collection [3, 4].
Pseudomonas aeruginosa is one of the main causes of
HAIs worldwide. Overall, it is considered to be the
fourth leading cause of HAIs [1]; P. aeruginosa is fre-
quently detected in patients with serious underlying con-
ditions, and is associated with poor prognosis and high
mortality [5]. Therapeutic options for P. aeruginosa in-
fections are limited due to its intrinsic resistant pattern
and its capacity to develop multiple drug resistance, ne-
cessitating the second-order or multiple antibiotic treat-
ment [6, 7].
Despite the prevalence of SSIs among HAIs [1], the
risk factors for P. aeruginosa in intraabdominal SSIs
have not been examined in detail. Given the high fre-
quency of elective colorectal surgery and the potential
serious outcomes associated with P. aeruginosa infec-
tions, it is essential to determine the predictive factors of
P. aeruginosa SSIs after colorectal surgery. The aim of
this study involving a large, multicenter, prospective co-
hort of patients undergoing elective colorectal surgery
was to identify specific predictive factors of P. aerugi-
nosa SSIs, with special focus on the role of preopera-
tive oral antibiotic prophylaxis, in order to propose
specific preventive measures and appropriate empir-
ical antibiotic treatment.
Methods
Setting and study patients
This was an observational, prospective cohort study of
3701 consecutive patients (age ≥ 18 years) who under-
went elective colorectal surgery between January 2011
and December 2014 at 10 Spanish hospitals belonging to
the VINCat Program [8]. VINCat is an HAI surveillance
program based on the National Healthcare Safety Net-
work (NHSN) model [9]. According to this program,
hospitals submit information regarding patients’ demo-
graphics and comorbidities, procedure characteristics,
microbiological and treatment data, as well as 30-day
postoperative outcomes [10]. Post-discharge surveillance
of SSIs until 30 days after surgery is mandatory and con-
sists of a review of the electronic clinical records in pri-
mary and secondary care, checking of readmissions and
emergency visits, and reviewing microbiological and
radiological data [11]. For the purpose of this study, data
prospectively collected from patients undergoing elective
colorectal surgery and who developed SSI caused by P.
aeruginosa and by other aetiologies were analysed.
Patients with pre-existing infection at the surgical site at
the time of surgery were excluded from the surveillance.
Study variables
Variables included in this study are described elsewhere
[12]. These variables included age, sex, American Society
of Anesthesiologists’ (ASA) physical status, administra-
tion of mechanical bowel preparation (MBP), oral anti-
biotic prophylaxis (OAP), surgical risk index category
based on the National Nosocomial Infections Surveil-
lance (NNIS) modified system criteria [13], adequacy of
the intravenous antibiotic prophylaxis, length of surgery
(prolonged surgery was considered as the duration of
surgery ≥75th percentile of the procedure), laparoscopic
surgery, wound classification, date of SSI, site of infec-
tion (superficial and deep incisional SSI or organ-space
(OS)-SSI, underlying disease (including neoplasia, in-
flammatory bowel disease and others), microbiology, and
antibiotic treatment. Age, ASA score, and NNIS modi-
fied risk index were dichotomized for the analysis.
Study outcomes included duration of antibiotic treat-
ment, length of stay (LOS), overall readmission, and over-
all mortality within 30 days of initial surgery. Readmission,
if any, was included in the LOS.
Definitions
SSIs were defined according to the Centers for Disease
Control and Prevention (CDC) [14] into incisional
(superficial and deep) and OS, and were stratified into
categories of surgical procedures (− 1 to 3) according to
the risk of surgical infection as defined by NHSN. Super-
ficial and deep incisional SSI were considered together
because the nature and management of these two types
of infection is similar, in contrast to OS-SSI, which
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significantly differs. SSI due to P. aeruginosa was de-
fined as the isolation of this microorganism from sur-
gical samples.
The NNIS modified risk index predicts the risk of SSIs
in colorectal surgery and range from − 1 to 2, depending
on the presence of one or more of the following factors:
ASA score III–V (1 point), contaminated or dirty-in-
fected surgery (1 point), length of surgery ≥75th percent-
ile of the procedure (1 point), and laparoscopic surgery
(− 1 point) [15]. This risk was calculated for all patients
in our cohort.
The intravenous antibiotic prophylaxis included second-
generation cephalosporin plus metronidazole administra-
tion, in accordance with the last consensus international
guidelines on antimicrobial prophylaxis [16]. The treat-
ment was deemed adequate, only when the antibiotics
were administered according to the local protocol at each
hospital, if the infusion was completed within 60 min of
the surgical incision, and perioperative redosing adminis-
tered (if indicated).
Administration of oral antibiotics in 2–3 doses a day
before surgery was considered as OAP. In addition, pa-
tients received MBP and the intravenous antibiotic
prophylaxis mentioned above. The use of OAP was not
mandatory but based on the local protocol at each hos-
pital. OAP included a combination of aminoglycoside
(neomycin 1 g, gentamicin 80 mg, or kanamycin 1 g)
with 1 g of metronidazole or 1 g of erythromycin [17].
The initial antibiotic treatment was either empirical or
targeted, depending on the availability of microbiological
sensitivity tests. The type and duration of antibiotic ther-
apy was decided by the attending surgeon according to
the local protocol. Source control was defined as any
procedure which resolved the infection focus or repaired
anatomical derangements. It was classified as reopera-
tion when a new surgical procedure was performed, re-
gardless of whether drainages were inserted or not.
Drainage was considered when percutaneous or trans-
rectal drainage was performed.
Treatment failure was defined as the persistence of
clinical and/or radiological symptoms/signs of SSIs or
all-cause mortality evaluated at 30 days post initial
surgery.
Microbiological studies
Surgical samples were collected in most patients (533/
669) with suspected SSIs, and blood cultures were per-
formed when indicated by the attending physician.
Polymicrobial infection was defined as isolation of ≥2 mi-
croorganisms in surgical samples; however, with ≥3 micro-
organisms isolated, identification was not performed.
The microdilution method, according to the Clinical
Laboratory Standard Institute (CLSI) guidelines, was
used to test and interpret antibiotic susceptibility [18].
Multidrug-resistant phenotypes were screened according
to the CLSI recommendations [19] and characterized by
PCR and DNA sequencing. The multidrug-resistant
gram-negative bacteria suspected were: (i) extended-
spectrum beta-lactamase (ESBL)-producing Enterobacte-
riaceae; (ii) carbapenemase-producing Enterobacteriaceae;
and (iii) multidrug-resistant strains of P. aeruginosa, re-
sistant to at least three of the following classes of antibi-
otics: carbapenems, ureidopenicillins, cephalosporins
(ceftazidime and cefepime), monobactams, aminoglyco-
sides, or fluoroquinolones.
Statistical analysis
Categorical variables were described as totals and frequen-
cies while continuous variables were described as medians
and interquartile ranges (IQR). Univariate analyses compar-
ing patients with SSIs caused by P. aeruginosa and patients
with SSIs caused by other microorganisms were performed
using the chi-square test or Fisher’s exact test for categor-
ical variables and the Mann–Whitney U test for continuous
variables. A multivariate logistic regression analysis which
included statistically significant and clinically relevant vari-
ables in the univariate analysis was performed to determine
independent predictive factors of P. aeruginosa SSI. A p
value of < 0.05 was considered to be statistically significant.
Results were given as odds ratios (OR) and 95% confidence
intervals (95% CI). The final model’s goodness-of-fit was
assessed by the Hosmer–Lemeshow test. Data were ana-
lyzed using the IBM SPSS 20.0 (Chicago, Ill., USA).
Results
Over the entire study period, 3701 patients were en-
rolled, and 669 (18%) developed SSIs. Of the 669 SSIs,
there were 62 (9.3%) P. aeruginosa SSIs, 29 incisional
SSIs, and 33 OS-SSIs. The number of P. aeruginosa SSIs
remained stable over the 4-year study period, as shown
in Fig. 1.
Fig. 1 Number of SSI caused by Pseudomonas aeruginosa per year.
P. aeruginosa: Pseudomonas aeruginosa, SSI: surgical site infections.
(%): percentage. This figure shows the percentage of surgical site
infections caused by Pseudomonas aeruginosa after elective colorectal
surgery in the whole cohort of patients
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Risk factor analysis
Patients with P. aeruginosa SSIs had higher ASA score
III–IV (67.7% vs 45.5%, p = 0.001, OR 2.5, 95% CI 1.44–
4.39), NNIS risk index 1–2 (74.2% vs 44.2%, p < 0.001,
OR 3.6, 95% CI 2.01–6.56), longer duration of surgery
(61.3% vs 41.4%, p = 0.003, OR 2.2, 95% CI 1.31–3.83),
and less frequently received OAP (17.7% vs 33.6%, p =
0.01, OR 0.4, 95% CI 0.21–0.83) compared to patients
with SSIs due to other organisms, as shown in Table 1.
Microbiological features
The comparison between patients with SSIs caused by P.
aeruginosa and those with SSIs caused by other microor-
ganisms is shown in Table 2. Of the 62 P. aeruginosa SSI
cases, two had concomitant bacteremia (one case of
P. aeruginosa and Bacteroides fragilis, and one of
Bacteroides spp). The SSIs caused by P. aeruginosa
were more frequently polymicrobial (67.7% vs 33.4%,
p < 0.001, OR 4.2, 95% CI 2.39–7.30) and less
frequently accompanied by gram-positive organisms
(16.1% vs 29.2%, p = 0.02, OR 0.4, 95% CI 0.23–0.94)
than SSIs caused by other microorganisms. Multidrug-re-
sistant P. aeruginosa was detected in three cases (4.8%).
There were no differences in the number of multidrug-re-
sistant Enterobacteriaceae isolated between patients with
P. aeruginosa SSIs and those with SSIs due to other
organisms.
Treatment
Among patients, 19 (65.5%) of 29 patients with P. aeru-
ginosa incisional SSIs received antibiotic treatment,
while all 33 patients (100%) with P. aeruginosa OS-SSIs
received antibiotics. The initial antibiotic management
of P. aeruginosa SSIs is shown in Table 3. Empirical
treatment had a median duration of 10 (IQR 6–16) days
and was switched to a targeted treatment in 33.3% of
cases. In 13 cases (28.8%), there was no further treat-
ment after empirical antibiotic. Targeted treatment, ei-
ther initial or after the empirical regimen, had a median
duration of 11 (IQR 7–18) days. Of the 33 patients with







*P-value OR (95% CI)
Age, median (IQR), years 69.6 (60.7–78) 71.3 (64.9–80) 69.9 (61.4–77) 0.1 1.0 (0.97–1.12)
Male sex, n (%) 1814 (59.8) 44 (71) 431 (71) 0.9 1.0 (0.56–1.78)
ASA III-IV, n (%) 1178 (38.9) 42 (67.7) 276 (45.5) 0.001 2.5 (1.44–4.39)
NNIS 1–2, n (%) 993 (32.8) 46 (74.2) 268 (44.2) < 0.001 3.6 (2.01–6.56)
Indication for surgery, n (%):
- Neoplasia 2868 (94.6) 57 (91.9) 577 (95.1) 0.3 0.5 (0.22–1.58)
- Inflammatory bowel disease 73 (2.4) 3 (4.8) 15 (2.5) 0.3 2.0 (0.56–7.13)
- Other 87 (2.9) 2 (3.2) 14 (2.3) 0.6 1.4 (0.31–6.36)
Type of surgery, n (%) 0.2 1.3 (0.81–2.33)
- Colon 2104 (69.4) 34 (54.8) 380 (62.6)
- Rectum 928 (30.6) 28 (45.2) 227 (37.4)
Adequate antibiotic prophylaxis, n (%) 2526 (83.3) 55 (88.7) 502 (82.7) 0.2 1.6 (0.73–3.37)
Duration of surgery ≥75th pa, n (%) 1163 (38.4) 38 (61.3) 251 (41.4) 0.003 2.2 (1.31–3.83)
Laparoscopic surgery, n (%) 1975 (65.1) 25 (40.3) 297 (48.9) 0.2 0.7 (0.41–1.29)
Detection of SSI during hospitalization, n (%) _ 46 (74.2) 435 (71.7) 0.6 1.1 (0.65–1.93)
Oral antibiotic prophylaxis, n (%) 1352 (44.6) 11 (17.7) 204 (33.6) 0.01 0.4 (0.21–0.83)
Mechanical bowel preparation, n (%) 2283 (77.1) 50 (80.6) 454 (75.8) 0.4 1.3 (0.69–2.56)
Ostomy, n (%) 715 (23.6) 29 (46.8) 218 (36) 0.09 1.5 (0.92–2.64)
Previous chemotherapy, n (%) 471 (15.5) 15 (24.2) 125 (20.6) 0.5 1.2 (0.66–2.26)
Previous radiotherapy, n (%) 452 (14.9) 14 (22.6) 112 (18.5) 0.4 1.3 (0.68–2.41)
Type of SSI, n (%): 0.6 1.1 (0.67–1.92)
- Incisional _ 29 (46.8) 304 (50.1)
- Organ-space _ 33 (53.2) 303 (49.9)
P. aeruginosa: Pseudomonas aeruginosa, SSI: surgical site infection, IQR: interquartile range, ASA: American Society of Anaesthesiologists’ physical status, NNIS:
National Nosocomial Infections Surveillance Risk Index
*P-value refers to comparison between P. aeruginosa SSI and other SSI
aLength of surgery greater than the 75th percentile of the procedure
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OS-SSI, 28 (84.8%) underwent source control of the infec-
tious focus, 19 underwent reoperation due to significant
anastomotic leakages while 9 underwent percutaneous
drainage due to small leakages or abscesses.
Outcomes
Patients with P. aeruginosa SSIs underwent a longer dur-
ation of antibiotic treatment (median 17 [IQR 10–24] vs
13 [IQR 8–20] days, p = 0.015, OR 1.1, 95% CI 1.00–
1.12), higher LOS (22 [IQR 15–42] vs 19 [IQR 12-28]
days, p = 0.02, OR 1.1, 95% CI 1.00–1.17), and higher
treatment failure rate (30.6% vs 20.8%, p = 0.07, OR 1.7,
95% CI 0.96–2.99) than patients with SSIs due to other
organisms, as shown in Table 4. There was no difference
in the mortality rate between the two groups.
Predictive factors
Multivariate logistic regression analysis of predictive fac-
tors for P. aeruginosa SSIs based on significant factors at
the univariate analysis level is shown in Table 5. ASA
Table 2 Microbiological features of SSI with or without Pseudomonas aeruginosa




P-value OR (95% CI)
Polymicrobial infection, n (%) 42 (67.7) 203 (33.4) < 0.001 4.2 (2.39–7.30)
Gram-negative bacteria, n (%) 28 (45.2) 262 (43.2) 0.7 1.1 (0.64–1.83)
- E. coli 17 (27.4) 212 (34.9) 0.2 0.7 (0.39–1.26)
• E. coli MDRa 4 (6.5) 24 (4) 0.3 1.6 (0.56–4.99)
- K. pneumoniae 3 (4.8) 27 (4.4) 0.8 1.1 (0.32–3.70)
• K. pneumoniae MDRa 1 (1.6) 8 (1.3) 0.8 1.2 (0.51–9.97)
Gram-positive bacteria, n (%) 10 (16.1) 177 (29.2) 0.02 0.4 (0.23–0.94)
- Enterococcus spp 6 (9.7) 111 (18.3) 0.08 0.4 (0.20–1.13)
• E. faecalis 4 (6.5) 54 (8.9) 0.5 0.7 (0.24–2.02)
• E. faecium 2 (3.2) 56 (9.2) 0.1 0.3 (0.07–1.37)
- S. aureus 3 (4.8) 26 (4.3) 0.8 1.1 (0.33–3.86)
- Coagulase negative staphylococci 1 (1.6) 12 (2) 0.8 0.8 (0.1–6-35)
Fungus, n (%) 1 (1.6) 19 (3.1) 0.5 0.5 (0.06–3.85)
- C. albicans 1 (1.6) 15 (2.5) 0.6 0.6 (0.08–4.98)
Anaerobes, n (%) 1 (1.6) 33 (5.4) 0.2 0.3 (0.03–2.12)
- B. fragilis 0 (0) 16 (2.6) 0.1 0.9 (0.88–0.92)
- C. perfringens 0 (0) 3 (0.5) 0.6 0.9 (0.88–0.92)
P. aeruginosa: Pseudomonas aeruginosa, SSI: surgical site infection, MDR: multidrug-resistant, E. Coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, A.
baumannii: Acinetobacter baumannii, E. faecalis: Enterococcus faecalis, E. faecium: Enterococcus faecium, S. aureus: Staphylococcus aureus, C. albicans: Candida
albicans, B. fragilis: Bacteroides fragilis, C. perfringens: Clostridium perfringens
aE. coli MDR and K. pneumoniae MDR are included in the box above referring to the organism group
Table 3 Initial antimicrobial management of P. aeruginosa SSI
Empirical (n = 45, 72.5%) Targeted (n = 7, 11.3%)
Antibiotic n (%) Antibiotic n (%)
Amoxicillin-clavulanic acid 15 (33.3) Piperacillin-tazobactam 2 (28.5)
Meropenem/Imipenem 13 (28.8) Meropenem 1 (14.2)
Piperacillin-tazobactam 9 (20) 3GC plus metronidazole 1 (14.2)
3GC 2 (4.4) FQ 1 (14.2)
FQ plus metronidazole 2 (4.4) 3GC 1 (14.2)
Aminoglycoside plus metronidazole 1 (2.2) FQ plus metronidazole 1 (14.2)
3GC plus metronidazole 1 (2.2)
Piperacillin-tazobactam plus cotrimoxazole 1 (2.2)
Antifungal
Fluconazole 1 (2.2)
SSI: Surgical site infection, 3GC: Third-generation cephalosporin, FQ: fluoroquinolone
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score and duration of surgery, that were significantly as-
sociated with P. aeruginosa SSI in the univariate analysis,
were not included in the multivariate analysis due to
their association with NNIS risk index. The independent
predictive factors for P. aeruginosa SSIs were NNIS risk
index (OR 2.3, 95% CI 1.03–5.40) and preoperative OAP
(OR 0.4, 95% CI 0.23–0.90).
Discussion
To the best of our knowledge, this is the first study to
identify the clinical characteristics and risk factors of P.
aeruginosa SSIs in a large cohort of patients undergoing
elective colorectal surgery. The main findings are that
NNIS modified risk index and OAP are associated with
the risk of development of SSIs caused by P. aeruginosa.
Majority of the patients in our cohort had colorectal
cancer. The intestinal microbiota of these patients
present specific characteristics, showing an increased
proportion of gram-negative bacteria, especially Entero-
bacteriaceae [20, 21]. However, P. aeruginosa does not
seem to play a relevant role in the intestinal microbiota
of patients, even with colorectal cancer. For this reason,
we did not expect to detect a high rate of P. aeruginosa
SSIs; however, we observed a rate of almost 10% in our
cohort. A partial explanation could be that the systemic
antimicrobial prophylaxis produced a selective antibiotic
pressure leading to overgrowth of P. aeruginosa. Fur-
thermore, tissue trauma and blood loss following a
major surgery as well as the use of drugs (such as
opioids) are associated with significant loss of diversity
and abundance of the gut normal microbiota. This leads
to an increase in the number and virulence of low-abun-
dance collagenase-producing intestinal microorganisms,
such as Enterococcus faecalis or P. aeruginosa, which
may favor SSI and ileus by modulating the immune re-
sponse of the host [22, 23]. OAP has been associated
with good postoperative outcomes, nevertheless, the
underlying changes in the gut microbiota are not com-
pletely known.
Previous studies have reported rates of P. aeruginosa
SSI similar to those observed in the present study, des-
pite the differences in patient characteristics (including
emergency surgery, intensive care unit admission, and
prior use of broad-spectrum antibiotics) [24, 25]. Pa-
tients with P. aeruginosa SSIs in our cohort had higher
ASA score and NNIS risk index, longer duration of sur-
gery, and lower levels of OAP. The study conducted by
Montravers et al. [26], which involved more than 300
patients with community-acquired and nosocomial
intraabdominal infections, revealed that P. aeruginosa
was more frequently isolated in nosocomial cases (in
more severely ill patients).
It should be noted that P. aeruginosa SSIs were more
frequently polymicrobial in nature than SSIs caused by
other organisms, as previously observed [24, 25]. It is
possible that the interaction of P. aeruginosa with other
gram-negative bacteria led to this clinical impact. We
observed a very low rate of multidrug-resistant P. aerugi-
nosa, explained by the short hospital stay of patients be-
fore surgery and the absence of prior long-term
antibiotic therapy.
Among patients with P. aeruginosa SSIs, the most fre-
quently used empiric antibiotic treatment failed to target
the organism. This suggests that the attending physicians
might not have considered Pseudomonas as the causative
agent. The role of the empiric antibiotic treatment in the
outcome of patients with intraabdominal infections has
been widely discussed [24, 26]; however, as we noted pre-
viously [12], it is generally accepted that the control of the
source of infection is the cornerstone of management in







*P-value OR (95% CI)
Duration of treatment, median (IQR), days _ 17 (10–24) 13 (8–20) 0.015 1.1 (1.00–1.12)
Treatment failure, n (%) _ 19 (30.6) 126 (20.8) 0.07 1.7 (0.96–2.99)
Readmission, n (%) 88 (2.9) 10 (16.1) 117 (19.3) 0.5 0.8 (0.39–1.63)







Length of stay, median (IQR), days 7 (5–10) 22 (15–42) 19 (12–28) 0.02 1.1 (1.00–1.17)
Mortality, n (%) 13 (0.4) 4 (6.5) 31 (5.1) 0.6 1.28 (0.43–3.75)
P. aeruginosa: Pseudomonas aeruginosa, SSI: surgical site infection, IQR: interquartile range
*P-value refers to comparison between P. aeruginosa SSI and other SSI
Table 5 Multivariate analysis of predictive factors of P. aeruginosa SSI
P. aeruginosa SSI/
Other SSI
P-value OR (95% CI)
NNIS 1–2, % 74.2/44.2 0.04 2.3 (1.03–5.40)
Rectal surgery, % 45.2/37.4 0.3 1.4 (0.70–2.70)
Oral antibiotic
prophylaxis, %
17.7/33.6 0.02 0.4 (0.23–0.90)
Ostomy, % 46.8/36 0.5 1.2 (0.60–2.30)
P. aeruginosa: Pseudomonas aeruginosa, SSI: surgical site infection, OR: Odds
Ratio, 95% CI: 95% confidence interval, ASA: American Society of Anaesthesiologists’
physical status. NNIS: National Nosocomial Infections Surveillance Risk Index
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severe cases [27, 28]. Most patients with P. aeruginosa
OS-SSIs in our cohort underwent source control.
Patients with P. aeruginosa SSIs had a longer anti-
biotic treatment, higher treatment failure, and longer
hospitalization than patients with SSIs caused by
other organisms. This reinforces the idea that P. aeru-
ginosa affects patients with more serious underlying
diseases and implies worse prognoses. However, we
did not observe differences in mortality rates between
patients with P. aeruginosa SSIs and SSIs caused by other
organisms, probably due to our low overall mortality rate,
neither did they observe differences, in studies previously
cited [24, 26]. As reported previously, treatment failure
among patients with the most serious SSIs in our cohort
was not associated with any microbiological etiology, in-
cluding P. aeruginosa [12].
The administration of OAP was a strong protective
factor against the development of P. aeruginosa SSIs.
Two previous outstanding studies [29, 30] based on the
large American College of Surgeons National Surgical
Quality Improvement Program (ACS-NSQIP) database,
showed a significant decrease in the rates of postopera-
tive incisional SSI, anastomotic leakage, ileus, and
30-day mortality in patients undergoing elective colorec-
tal procedures who received MBP and OAP (compared
to patients who had received MBP or OAP alone, or
those who had not received any preparation). We also
showed a reduction in the OS-SSI rate with the use of
MBP combined with OAP [31]. Some authors have how-
ever suggested the same benefit in the use of OAP with-
out MBP [32], but this need to be validated in further
large multicenter randomized controlled trials.
The most appropriate combination of oral antibiotics
has not been clearly stated. In our study, the most fre-
quently used aminoglycoside was neomycin, since its
poor absorption in the digestive tract allows all its effects
to be concentrated in the intestinal lumen. This specific
characteristic, which also rules it out for the treatment
of systemic infections, may justify its good activity
against P. aeruginosa. Although the use of OAP in elect-
ive colorectal surgery has been recommended in recent
World Health Organization guidelines [33, 34], many
hospitals have abandoned this practice over the last dec-
ade since MBP has been shown to be ineffective [35].
Since OAP is administered together with MBP, the use
of OAP was also abandoned. Although evaluation of
OAP was not an objective in our study, our results
reinforce the use of OAP combined with MBP in redu-
cing P. aeruginosa SSI rates.
This study has some limitations. First, the hospitals in
our study differed in terms of size, characteristics, levels
of activity, and type of preoperative oral preparation. As
previously mentioned OAP was not administered in a
uniform manner but according to local protocols that
did not depend on the baseline characteristics of pa-
tients. However, all hospitals followed the VINCat rec-
ommendations and CLSI microbiological guidance.
Second, because of the nature of our study, we could
not exclude bias related to risk factors not included in
the study. However, the large number of patients and
the consistent collection of the data by expert infection
control staffs, support the results.
Conclusions
SSIs due to P. aeruginosa after elective colorectal surgery
mainly occur in patients with a high NNIS risk index
and in those who do not receive OAP. We recommend
empirical antibiotic treatment covering the multi-sus-
ceptible P. aeruginosa in more severely ill patients who
develop SSIs but do not receive OAP. We observed
worse outcomes in patients with P. aeruginosa SSIs, as
demonstrated by the need for longer antibiotic treatments,
higher treatment failure, and higher LOS. Further studies
are needed to prove the effectiveness of OAP in the pre-
vention of P. aeruginosa SSIs after colorectal surgery.
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